These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36707268)

  • 1. Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression.
    Singh B; Vande Voort JL; Riva-Posse P; Pazdernik VM; Frye MA; Tye SJ
    Biol Psychiatry; 2023 Jun; 93(12):e65-e68. PubMed ID: 36707268
    [No Abstract]   [Full Text] [Related]  

  • 2. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
    Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
    Kantrowitz JT; Halberstam B; Gangwisch J
    J Clin Psychiatry; 2015 Jun; 76(6):737-8. PubMed ID: 26132675
    [No Abstract]   [Full Text] [Related]  

  • 6. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine for Treatment-Resistant bipolar depression-A reality check!
    Singh B
    Bipolar Disord; 2023 May; 25(3):247-248. PubMed ID: 36978284
    [No Abstract]   [Full Text] [Related]  

  • 10. Ketamine for treatment-resistant bipolar depression-need for more data!
    Singh B; Vande Voort JL; Kung S
    Bipolar Disord; 2021 Nov; 23(7):728-729. PubMed ID: 34549861
    [No Abstract]   [Full Text] [Related]  

  • 11. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
    J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
    Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
    Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for use of ketamine to treat depression in Australia and New Zealand.
    Bayes A; Dong V; Loo C
    Aust N Z J Psychiatry; 2019 Nov; 53(11):1117-1120. PubMed ID: 31364369
    [No Abstract]   [Full Text] [Related]  

  • 14. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression.
    Ford N; Ludbrook G; Galletly C
    Aust N Z J Psychiatry; 2015 Dec; 49(12):1227. PubMed ID: 26058787
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.
    Saligan LN; Luckenbaugh DA; Slonena EE; Machado-Vieira R; Zarate CA
    J Affect Disord; 2016 Apr; 194():115-9. PubMed ID: 26807672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression.
    Rybakowski JK; Permoda-Osip A; Bartkowska-Sniatkowska A
    Int J Psychiatry Clin Pract; 2017 Jun; 21(2):99-103. PubMed ID: 28271731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.